Cargando…
A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors
B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Raf inhibitors (BRIs), 3D pharmacophore models were created using the Genetic Algorithm with Linear Assignment of Hypermolecular Alignment of Database (GALAHAD). The best pharmacophore model obtained wh...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490445/ https://www.ncbi.nlm.nih.gov/pubmed/26035757 http://dx.doi.org/10.3390/ijms160612307 |
_version_ | 1782379505208262656 |
---|---|
author | Xie, Huiding Chen, Lijun Zhang, Jianqiang Xie, Xiaoguang Qiu, Kaixiong Fu, Jijun |
author_facet | Xie, Huiding Chen, Lijun Zhang, Jianqiang Xie, Xiaoguang Qiu, Kaixiong Fu, Jijun |
author_sort | Xie, Huiding |
collection | PubMed |
description | B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Raf inhibitors (BRIs), 3D pharmacophore models were created using the Genetic Algorithm with Linear Assignment of Hypermolecular Alignment of Database (GALAHAD). The best pharmacophore model obtained which was used in effective alignment of the data set contains two acceptor atoms, three donor atoms and three hydrophobes. In succession, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed on 39 imidazopyridine BRIs to build three dimensional quantitative structure-activity relationship (3D QSAR) models based on both pharmacophore and docking alignments. The CoMSIA model based on the pharmacophore alignment shows the best result (q(2) = 0.621, r(2)(pred) = 0.885). This 3D QSAR approach provides significant insights that are useful for designing potent BRIs. In addition, the obtained best pharmacophore model was used for virtual screening against the NCI2000 database. The hit compounds were further filtered with molecular docking, and their biological activities were predicted using the CoMSIA model, and three potential BRIs with new skeletons were obtained. |
format | Online Article Text |
id | pubmed-4490445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-44904452015-07-07 A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors Xie, Huiding Chen, Lijun Zhang, Jianqiang Xie, Xiaoguang Qiu, Kaixiong Fu, Jijun Int J Mol Sci Article B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Raf inhibitors (BRIs), 3D pharmacophore models were created using the Genetic Algorithm with Linear Assignment of Hypermolecular Alignment of Database (GALAHAD). The best pharmacophore model obtained which was used in effective alignment of the data set contains two acceptor atoms, three donor atoms and three hydrophobes. In succession, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed on 39 imidazopyridine BRIs to build three dimensional quantitative structure-activity relationship (3D QSAR) models based on both pharmacophore and docking alignments. The CoMSIA model based on the pharmacophore alignment shows the best result (q(2) = 0.621, r(2)(pred) = 0.885). This 3D QSAR approach provides significant insights that are useful for designing potent BRIs. In addition, the obtained best pharmacophore model was used for virtual screening against the NCI2000 database. The hit compounds were further filtered with molecular docking, and their biological activities were predicted using the CoMSIA model, and three potential BRIs with new skeletons were obtained. MDPI 2015-05-29 /pmc/articles/PMC4490445/ /pubmed/26035757 http://dx.doi.org/10.3390/ijms160612307 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xie, Huiding Chen, Lijun Zhang, Jianqiang Xie, Xiaoguang Qiu, Kaixiong Fu, Jijun A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors |
title | A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors |
title_full | A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors |
title_fullStr | A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors |
title_full_unstemmed | A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors |
title_short | A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors |
title_sort | combined pharmacophore modeling, 3d qsar and virtual screening studies on imidazopyridines as b-raf inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490445/ https://www.ncbi.nlm.nih.gov/pubmed/26035757 http://dx.doi.org/10.3390/ijms160612307 |
work_keys_str_mv | AT xiehuiding acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT chenlijun acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT zhangjianqiang acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT xiexiaoguang acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT qiukaixiong acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT fujijun acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT xiehuiding combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT chenlijun combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT zhangjianqiang combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT xiexiaoguang combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT qiukaixiong combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors AT fujijun combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors |